Related Experiment Video
Updated: Sep 3, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Should Bilateral Internal Thoracic Arteries be Used in Patients with Chronic Kidney Disease?
German J Chaud1, Dimitri Kalavrouziotis1, Stéphanie Dionne1
1Department of Cardiac Surgery, and Research Center, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.
Insights
Patients with chronic kidney disease (CKD) undergoing coronary artery bypass grafting (CABG) with bilateral internal thoracic artery (BITA) strategy showed similar survival and cardiovascular readmission rates compared to those without CKD. However, CKD patients had a higher risk of renal readmissions.
Area of Science:
- Cardiovascular Surgery
- Nephrology
- Transplantation
Background:
- Preoperative renal dysfunction significantly impacts outcomes after cardiac surgery.
- Chronic kidney disease (CKD) is a critical factor influencing mortality in patients undergoing coronary artery bypass grafting (CABG).
Purpose of the Study:
- To evaluate the early and long-term results of CABG using a bilateral internal thoracic artery (BITA) strategy in patients with preoperative CKD.
- To compare outcomes between CKD and non-CKD patients undergoing BITA-CABG.
Main Methods:
- Retrospective analysis of 2,111 patients undergoing BITA-CABG between 2000 and 2019.
- One-to-many propensity score matching created cohorts of 132 CKD patients and 358 non-CKD patients.
- Primary endpoint: late freedom from all-cause mortality; secondary endpoint: late hospital readmissions.
Main Results:
- In-hospital mortality was similar between CKD (0.8%) and non-CKD (0%) groups (P=0.31).
- Median follow-up of 6.9 years showed no significant difference in overall survival (HR 1.37, P=0.17).
- Cardiovascular readmissions were comparable, but renal readmissions were higher in the CKD group (6.7% vs 1.2%).
Conclusions:
- In patients undergoing BITA-CABG, CKD is not associated with increased early or late mortality.
- CKD patients did not have a higher risk of cardiovascular readmission after BITA-CABG.
- The risk of hospital readmission for renal causes is elevated in CKD patients post-CABG.
Abstract:
Preoperative renal dysfunction is a major determinant of operative and long-term mortality following cardiac surgery. The objective of this study was to assess early and long-term results of CABG in patients with preoperative chronic kidney disease (CKD) using a bilateral internal thoracic artery (BITA) strategy, compared to those without CKD. We retrospectively analyzed data for 2,111 consecutive patients who underwent CABG with BITA between 2000 and 2019. One-to-many propensity score matching was performed to produce a cohort of 132 patients with CKD (defined as an estimated glomerular filtration rate <60 mL/min/1.73 m2), matched to 358 patients with normal renal function (non-CKD). The primary end-point of interest was late freedom from all-cause mortality. Late hospital readmissions were also assessed. Mean eGFR and serum creatinine were: 49.8 versus 84.3 mL/min/m2 and 146.1 versus 83.6 µmol/L (CKD vs non-CKD, P< 0.001). In-hospital outcomes were similar among matched patients, including mortality (CKD 0.8% vs non-CKD 0%, P= 0.31). At a median follow-up of 6.9 years, there was no significant difference in survival between both groups (hazard ratio (HR) 1.37, 95% confidence interval (CI) 0.87-2.16, P= 0.17). Hospital readmission for cardiovascular causes (including repeat coronary revascularization) was comparable between the 2 groups. However, the risk of hospital readmission for renal causes was higher in patients with CKD (6.7%) compared to non-CKD (1.2%). In a propensity score-matched cohort of patients undergoing BITA-CABG, CKD was not associated with increased early or late mortality, nor was there a greater risk of hospital readmission for cardiovascular events.
Related Concept Videos
Kidney Transplant I: Introduction
Hemodialysis I: Introduction
Cardiac Catheterization I: Pre-Procedure Overview
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

